The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), and New Delhi based Panacea Biotec have announced cooperation to produce 100 million doses per year of Sputnik V, the world’s first registered vaccine against coronavirus.

Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF.

To date Sputnik V has been registered in 59 countries globally with total population of over 1.5 billion people. Efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet, one of the world's oldest and most respected medical journals.

Dr. Rajesh Jain, Managing Director of Panacea Biotec, said:

“We are pleased to collaborate with RDIF to produce Sputnik V for global markets. Panacea Biotec brings decades of vaccine manufacturing and distribution know-how to scale-up Sputnik V supplies. Panacea Biotec will produce Sputnik V in its internationally accredited facilities complying to strict GMP standards and prequalified by WHO.”